ODR Daily Brief: 2026-08-16
Industry intelligence for the people who run hormone, peptide, and GLP-1 clinics. One read, then back to work.
3 items. 4-minute read.
Lead story
States enforce compounding above the federal floor
Sheppard Mullin published an August 6, 2026 survey of how states regulate compounded GLP-1s and peptides. The eligibility baseline is federal, under 503A and 503B. No state can go below that floor. Where states diverge is enforcement intensity and the sourcing conditions they add on top.
The firm splits the map into five groups. California is the outlier. Compounding rules effective October 1, 2025 require a documented, clinically significant patient-specific difference. The certificate of analysis must name the active-ingredient manufacturer, not the distributor. Ohio and Washington are the enforcers. Ohio's July 2025 guidance treats post-shortage semaglutide and tirzepatide copies as closed. The board has summarily suspended more than thirty clinics and medical spas since the start of 2025. Washington issued a stop-service order on a GLP-1 sterile compounder. Connecticut, Illinois, and South Carolina are running consumer-protection cases that do not depend on what the pharmacy board said. Texas and Florida sit with the silent majority and rest on the federal floor.
Two federal tracks sit under that map. Twelve peptides came off Category 2 in April 2026 and were not moved into Category 1. Removal is not permission. GLP-1 copies lost the shortage pathway. FDA has since tightened the copy standard. It has also proposed keeping semaglutide, tirzepatide, and liraglutide off the 503B bulks list.
The eligibility question is federal. The enforcement question is the state that licenses the shop.
Our take. The federal floor answers what may be compounded. It does not answer who will knock. Why would a Texas clinic and an Ohio clinic, running the same vial, face different weeks? Because Ohio's board has already suspended more than thirty shops this year, and Texas has not written a GLP-1 position at all. Sheppard's map is the operator document. California is the only state that wrote a stricter rule. A handful of AGs are using consumer-protection statutes that do not care what the pharmacy board said. A program built only to the federal floor is built to the quiet states.
The Signal
Regulatory
Alston reads the July 29 Hims complaint as a ROSCA disclosure case
The FTC, California, and Utah sued Hims & Hers on July 29 in the Northern District of California. An Alston & Bird advisory on August 10 draws out the cut that did not run in Friday's Venable recap: the complaint treats the failure to disclose health-data sharing with advertising platforms as a material term under ROSCA, the statute that governs what a subscription business must disclose before it charges. These are allegations in a complaint, not findings. The company has not answered.
Also on the wire
PCAC's July vote is still a recommendation, and Category 1 discretion is still open. Sheppard Mullin on August 7 recapped the July 23-24 meeting. The committee recommended six of seven nominated peptides for the 503A bulks list. Emideltide failed. The votes are advisory. FDA decides later, by notice-and-comment rulemaking that the firm says could run into 2027 or 2028. Whether the six go onto an interim Category 1 list pending that rulemaking remains open. Listing is not approval. A recommendation is not a listing.
Forward this to an operator who needs it.
Filed by the ODR desk.
Corrections: [email protected]. Fixes run at the top of the next issue.
How we source and correct: go.optimized.news
ODR is industry intelligence, not legal or medical advice. Decisions about your practice belong with your counsel and your medical director.